^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TAC-003
i
Other names: TAC-003, Nectin-4 TRAAC
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Tallac Therap
Drug class:
TLR9 agonist, Nectin-4 inhibitor
Related drugs:
2years
A Nectin-4 targeted TLR9 agonist antibody conjugate induces robust immune cell activation and anti-tumor responses (SITC 2022)
Animals in which Nectin-4 TRAAC treatment led to tumor clearance were protected from tumor growth upon rechallenge, demonstrating that Nectin-4 TRAAC induces potent anti-tumor immunological memory. Conclusions The preclinical data shown here provide a strong rationale for pursuing Nectin-4 TRAAC for the treatment of Nectin-4-expressing solid tumors, including those that are refractory to CPI therapy.
IO biomarker
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
TAC-003
Share via
